Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis
Open Access
- 16 February 2021
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 100 (4) , 969-978
Abstract
A head-to-head comparison of outcomes of unrelated donor allogeneic peripheral blood stem cell transplantation for AML between reduced intensity conditioning (RIC) and myeloablative conditioning (MAC) regimens using thymoglobulin for GVHD prophylaxis is limited. We evaluated outcomes of 122 AML patients who received either busulfan (Bu)/fludarabine (Flu)/low-dose total body irradiation (TBI) as RIC (n = 64, 52%) or Bu/Flu as MAC (n = 58, 48%), and thymoglobulin 4.5 mg/kg total dose between day − 3 to − 1 for GVHD prophylaxis. Grades III–IV acute GVHD (aGVHD) was lower with Bu/Flu/TBI compared with Bu/Flu (6.2% vs 26.1%, p = 0.009). At 1 year, Bu/Flu/TBI was associated with similar chronic GVHD (41.2% vs 44.8%, p = 0.75), OS (61.9% vs 56.9%, p = 0.69), relapse rate (29.9% vs 20.7%, p = 0.24), relapse-free survival (52.8% vs 50%, p = 0.80), non-relapse mortality (17.4% vs 29.3%, p = 0.41), and GVHD-free relapse-free survival (24.2% vs 27.5%, p = 0.80) compared with Bu/Flu. Multivariable analysis did not reveal any difference in outcomes between both regimens. In summary, thymoglobulin at 4.5 mg/kg did not have any adverse impact on survival when used with RIC regimen. Both Bu/Flu/TBI and Bu/Flu conditioning regimens yielded similar survival.Keywords
This publication has 41 references indexed in Scilit:
- Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First RemissionTransplantation and Cellular Therapy, 2011
- Fludarabine, Antithymocyte Globulin, and Very Low-Dose Busulfan for Reduced-Intensity Conditioning before Allogeneic Stem Cell Transplantation in Patients with Lymphoid MalignanciesTransplantation and Cellular Therapy, 2011
- Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignanciesBlood, 2011
- TBI during BM and SCT: review of the past, discussion of the present and consideration of future directionsBone Marrow Transplantation, 2010
- Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Allogeneic stem cell transplantation for acute myeloid leukemiaHaematologica, 2010
- Antithymocyte Globulin Impairs T-Cell/Antigen-Presenting Cell Interaction: Disruption of Immunological Synapse and Conjugate FormationTransplantation, 2007
- Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of ageBlood, 2005
- Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantationTransplantation and Cellular Therapy, 2004
- Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 yearsBlood, 2003